Combining the oral drug ixazomib and lower-dose lenalidomide shows important reductions in neutropenia and peripheral ...

"We are well aware that four-drug regimens with anti-CD38 monoclonal antibodies, lenalidomide, proteasome inhibitors, and ...

Iberdomide is a member of a new drug class in myeloma known as CELMoD agents, which build on the established platform of ...

A growing list of contemporary phase 3 trials have shown that more drugs (quadruplet therapies) are superior to less drugs ...

An FDA AdCom voted for a new intermediate endpoint of MRD for accelerated approvals in multiple myeloma in 2024.

T-cell therapy continues to move into earlier lines of treatment for patients with relapsed/refractory multiple myeloma. Adriana Rossi, MD, assista ...

TORONTO -- A three-drug combination involving the B-cell maturation antigen (BCMA)-CD3 bispecific antibody elranatamab ...

Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and ...

Subcutaneous isatuximab plus bortezomib, lenalidomide, and dexamethasone is effective in transplant-ineligible, newly diagnosed multiple myeloma.

Iberdomide, which is being positioned as a successor to Revlimid, will continue in EXCALIBER-RRMM as the study progresses to ...

Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...

"C4’s multiple myeloma drug to reach pivotal trials after Phase I victory" was originally created and published by Clinical ...